These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39202384)

  • 1. Aberrantly Expressed tRNA-Val Fragments Can Distinguish Canine Hepatocellular Carcinoma from Canine Hepatocellular Adenoma.
    Hashimoto S; Hasan MDN; Arif M; Nozaki N; Husna AA; Furusawa Y; Sogawa T; Takahashi K; Kuramoto T; Noguchi A; Takahashi M; Yamato O; Rahman MM; Miura N
    Genes (Basel); 2024 Aug; 15(8):. PubMed ID: 39202384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Y RNA-Derived Fragments Can Differentiate Canine Hepatocellular Carcinoma from Hepatocellular Adenoma.
    Ushio N; Hasan MN; Arif M; Miura N
    Animals (Basel); 2023 Sep; 13(19):. PubMed ID: 37835660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Borderline Hepatocellular Adenomas: A Practical Diagnostic Approach Based on Pathologic and Molecular Features.
    Poté N; Caruso S; Caderaro J; Cauchy F; Lagadec F; Couchy G; Raffenne J; Augustin J; Vernuccio F; Vilgrain V; Hercent A; Theou-Anton N; Zucman-Rossi J; Paradis V
    Mod Pathol; 2023 Sep; 36(9):100211. PubMed ID: 37169258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma.
    Chen ZM; Crone KG; Watson MA; Pfeifer JD; Wang HL
    Am J Surg Pathol; 2005 Dec; 29(12):1600-8. PubMed ID: 16327432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Klotho expression and its prognostic significance in canine hepatocellular carcinoma.
    Kim G; Chung H; Lee S; Kim WH
    Vet Comp Oncol; 2023 Mar; 21(1):91-99. PubMed ID: 36482288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma.
    Lai YC; Ushio N; Rahman MM; Katanoda Y; Ogihara K; Naya Y; Moriyama A; Iwanaga T; Saitoh Y; Sogawa T; Sunaga T; Momoi Y; Izumi H; Miyoshi N; Endo Y; Fujiki M; Kawaguchi H; Miura N
    Vet Comp Oncol; 2018 Jun; 16(2):288-296. PubMed ID: 29314614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Needle tract seeding and malignant transformation of hepatocellular adenoma into well-differentiated hepatocellular carcinoma in a dog.
    Jornet-Rius O; Agulla B; López MC; Viñeta C; García-Ferrer A; Serrano B; Marco A; Palomares A; Novellas R; Espada Y; Roura X; Solano-Gallego L
    Vet Clin Pathol; 2023 Sep; 52(3):507-513. PubMed ID: 37202832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing.
    Zheng J; Sadot E; Vigidal JA; Klimstra DS; Balachandran VP; Kingham TP; Allen PJ; D'Angelica MI; DeMatteo RP; Jarnagin WR; Ventura A
    PLoS One; 2018; 13(7):e0200776. PubMed ID: 30052636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers.
    Chiu LY; Kishnani PS; Chuang TP; Tang CY; Liu CY; Bali D; Koeberl D; Austin S; Boyette K; Weinstein DA; Murphy E; Yao A; Chen YT; Li LH
    J Gastroenterol; 2014 Aug; 49(8):1274-84. PubMed ID: 24129885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezrin as a possible diagnostic and/or prognostic biomarker in mice lymphatic metastatic hepatocellular carcinoma in vivo.
    Bakheet AMH; Mahmoud SA; Huang Y; Zhang J; Wang J; Wei Y; Gamallat Y; Awadasseid A; Owusu L; Khidir Y; Wang L; Zhou S; Seewooruttun PK; Xin B; Xuan W; Su Z; Tang J
    Biofactors; 2017 Sep; 43(5):662-672. PubMed ID: 28608644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exome sequencing-based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma.
    Bu Y; Huang R; Gao J; Qu W; Fu X; Liu W; Ding Z; Zhou J; Fan J; Wang X; Chen D; Tang Z
    Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13901. PubMed ID: 38843867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular adenomas: review of pathological and molecular features.
    Beaufrère A; Paradis V
    Hum Pathol; 2021 Jun; 112():128-137. PubMed ID: 33307077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.
    Ramos-Vara JA; Miller MA; Johnson GC
    Vet Pathol; 2001 Nov; 38(6):636-43. PubMed ID: 11732796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YRNA and tRNA fragments can differentiate benign from malignant canine mammary gland tumors.
    Hasan MN; Rahman MM; Husna AA; Nozaki N; Yamato O; Miura N
    Biochem Biophys Res Commun; 2024 Jan; 691():149336. PubMed ID: 38039834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.
    Zou RC; Liang Y; Li LL; Tang JZ; Yang YP; Geng YC; He J; Luo LY; Li WX; Sun ZW; Yuan HL
    Med Sci Monit; 2019 Nov; 25():8618-8627. PubMed ID: 31730575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.
    Haas S; Merkelbach-Bruse S; Justenhoven C; Brauch H; Fischer HP
    Pathol Res Pract; 2009; 205(10):716-25. PubMed ID: 19596526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice.
    Shin S; Wangensteen KJ; Teta-Bissett M; Wang YJ; Mosleh-Shirazi E; Buza EL; Greenbaum LE; Kaestner KH
    Hepatology; 2016 Oct; 64(4):1163-1177. PubMed ID: 27099001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
    Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
    J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
    Zhan K; Bai Y; Liao S; Chen H; Kuang L; Luo Q; Lv L; Qiu L; Mei Z
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.